Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569344 · ClinicalTrials.gov registry record
COVID-19 and Venous Thromboembolism Risk
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 398,530
- Enrollment target
NCT04569344: Completed study, sponsored by University of California, San Francisco.
NCT04569344 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 398,530 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04569344 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 398,530 participants
- Enrollment target
Study Summary
Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.
Primary Outcome
VTE will be defined as a clinical encounter with evidence of acute VTE, identified by diagnosis codes, +/- radiology procedure codes
Interventions
- OTHER Laboratory test positive for SARS-CoV-2 virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398,530 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2022-06-21 |
What the finished NCT04569344 record still lists
NCT04569344 is an observational study that tracks outcomes without assigning an intervention. Its 398,530 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Laboratory test positive for SARS-CoV-2 virus is the first listed.
NCT04569344 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04569344 about?
NCT04569344 is a clinical study titled "COVID-19 and Venous Thromboembolism Risk". Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evalu...
What is the current status of trial NCT04569344?
This trial is currently completed. The enrollment target is 398,530 participants. The study started on 2020-01-01. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04569344?
The interventions under investigation include: Laboratory test positive for SARS-CoV-2 virus (OTHER).
Who is sponsoring clinical trial NCT04569344?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI